0001628280-26-013337
SEC filingRevenue growth driven by imaging volume and mix shift, but operating margin compressed by higher costs; Digital Health expands.
RadNet describes itself as a leading national provider of diagnostic imaging services in the United States, based on number of locations and annual imaging revenue. The company has been in business since 1985 and as of December 31, 2025, operated 418 imaging centers directly or through joint ventures across nine states: Arizona, California, Delaware, Florida, Maryland, Virginia, New Jersey, Texas, and New York. The company also has an international presence through its majority-owned subsidiary, HLH Imaging Group, which provides teleradiology services in the United Kingdom.
RadNet operates two principal business segments: Imaging Centers and Digital Health. The Imaging Centers segment provides diagnostic imaging services including MRI, CT, PET, nuclear medicine, mammography, ultrasound, X-ray, and fluoroscopy at fixed-site, freestanding outpatient centers and through hospital joint ventures. The vast majority of centers offer multi-modality imaging, which diversifies revenue streams and reduces exposure to reimbursement changes. The Digital Health segment, led by the DeepHealth subsidiary, develops and deploys AI-powered health informatics solutions including DeepHealth OS (a cloud-native operating system for radiology service lines), eRad RIS/PACS, and clinical AI applications for breast, lung, and prostate imaging. This segment has 22 FDA clearances and 15 CE marks and serves over 2,000 customers globally.
Key products and platforms include DeepHealth OS, eRad RIS/PACS, and AI suites from acquisitions such as Aidence (lung imaging), Quantib (prostate imaging), Kheiron (mammography AI), ICAD (breast cancer detection), See Mode, and CIMAR (image exchange platform). These are marketed as a comprehensive portfolio of AI-enabled health informatics solutions covering enterprise operations, enterprise imaging, and clinical AI.
RadNet's go-to-market strategy employs a multi-pronged approach: physician marketing through customer service representatives who liaison with referring physicians; payor marketing to solicit and manage contracts with managed care organizations and insurers; and a sports marketing program targeting professional sports organizations such as the Los Angeles Dodgers, Kings, Lakers, Anaheim Ducks, and others. The company does not disclose customer concentration; revenue is derived from a diverse payor mix including commercial insurance, managed care capitation, Medicare (23.4% of imaging center net service revenue), and Medicaid (2.5%).
Competitors include independent imaging operators, smaller regional operators, hospitals and hospital groups with their own imaging services, and physician practices that have established in-house imaging centers. Competitive differentiation is based on reputation, multi-modality offerings, center locations, service quality, and relationships with healthcare providers and referring physicians.
RadNet's business strategy comprises six pillars: (1) maximizing performance at existing centers by expanding physician relationships and procedure offerings; (2) focusing on profitable contracting through regular renegotiation of payor contracts; (3) optimizing operating efficiencies through equipment utilization and cost reduction; (4) expanding networks organically and via acquisitions in existing and new markets; (5) expanding joint ventures with hospitals; and (6) advancing a cloud-first, AI-powered digital health platform (DeepHealth) to enhance operations and commercialize the Digital Health segment.
As of December 31, 2025, RadNet employed 8,844 full-time, 432 part-time, and 1,988 per diem employees, including 222 full-time physicians and 2,835 full-time technologists. The company emphasizes diversity, equity, inclusion, and belonging, and provides training, tuition reimbursement, and wellness programs.
For fiscal year 2025, RadNet reported total consolidated revenue of $2.04 billion, an increase of 11.5% from $1.83 billion in 2024. Revenue growth was primarily driven by the Imaging Center segment, which saw a 10.9% increase to $1.99 billion, supported by higher imaging procedure volumes and a favorable shift toward advanced imaging modalities such as PET/CT. However, operating income declined sharply to $61.2 million (3.0% margin) from $104.3 million (5.7% margin) in the prior year. The compression was driven by a 13.2% increase in operating expenses, including higher salaries and professional fees (up 10.1%), medical supplies (up 22.2%), and lease abandonment charges ($8.6 million vs. $2.5 million). Net loss attributable to common stockholders was $(18.7) million, compared to net income of $2.8 million in 2024, impacted by higher interest expense ($69.9 million) and non-cash hedge losses ($7.1 million).
The Imaging Centers segment remained the dominant revenue contributor, but its operating margin contracted due to cost pressures. The segment's operating income was $94.3 million (4.7% margin) compared to an estimated $119.5 million (6.7% margin) in 2024. Cost increases were driven by higher staffing levels to support volume, wage inflation (including California's minimum wage increase for healthcare workers), and a shift toward higher-cost medical supplies for advanced imaging. Lease abandonment charges rose as the company closed seven underperforming centers.
The Digital Health segment posted strong revenue growth of 41.1% to $92.7 million, reflecting a 64.9% increase in AI-related revenue and a 29.0% rise in Enterprise Imaging. However, the segment recorded an operating loss of $(32.3) million, widening from $(14.9) million in 2024, due to increased stock-based compensation, R&D spending ($20.2 million non-capitalized), and costs from recent acquisitions (iCAD, See-Mode, CIMAR). Management expects the segment to continue operating at a net loss in the near term as integration progresses.
Management's outlook indicates a continued focus on expanding the Digital Health platform through integration of acquired companies (iCAD, See-Mode, CIMAR) and investment in AI and cloud-based solutions. There is no specific forward guidance provided, but the company expects to fund operations through cash flow from operations, existing credit facilities, and access to capital markets. The MD&A highlights that the recent acquisitions will contribute to Digital Health's growth but will weigh on near-term profitability. The Imaging Center segment is expected to benefit from organic volume growth and acquisitions, though cost inflation and lease optimization remain key margin considerations. Adjusted EBITDA, a non-GAAP metric, grew 7.4% to $300.2 million in 2025, signaling underlying cash flow strength despite GAAP net losses.
As of December 31, 2025, RadNet held $767.2 million in cash and equivalents, up from $740.0 million a year earlier. Total debt stood at $1,089.9 million, consisting primarily of $961.1 million in Barclays term loans (net of discount) and $123.8 million in Truist term loans, plus $17.3 million in equipment notes. The company had no outstanding balances on its $282.0 million Barclays revolver or $50.0 million Truist revolver, providing $323.0 million in undrawn capacity. Total equity increased to $1.36 billion from $1.13 billion, driven by stock issuance and retained earnings despite a net loss attributable to common stockholders of $18.7 million.
RadNet's most significant contractual obligations are operating leases, with total future lease payments of $1.12 billion as of December 31, 2025. Of this, $113.4 million is due in 2026. The company also has $1.10 billion in notes payable maturities, with $27.9 million due in 2026. Additionally, RadNet has contingent consideration liabilities totaling $15.0 million related to recent acquisitions (See-Mode, Kolb, CIMAR) and $12.2 million in operating leases that have not yet commenced.
The company did not repurchase any shares or pay dividends in 2025. Capital expenditures totaled $213.3 million, representing 10.5% of revenue, primarily for imaging equipment and leasehold improvements. Debt activities included $99.0 million in new borrowings (incremental term loan) and $27.8 million in principal repayments, resulting in a net debt increase of $73.7 million. Proceeds from stock option exercises were $5.4 million. No public equity offerings occurred in 2025; the last was in March 2024.
RadNet operates two segments: Imaging Center and Digital Health. Imaging Center generated $1.99 billion in external revenue (97.4% of total), up 10.9% year-over-year, with segment profit of $242.2 million (12.2% margin). Digital Health external revenue reached $52.0 million, up 39.3%, but segment loss widened to $15.3 million from $3.4 million, reflecting investment in AI and software development. Geographically, 98.3% of total revenue came from the United States ($2.01 billion), with the remainder from other countries ($34.0 million). Segment balance sheet data is not reported.
RadNet faces significant exposure to adverse economic conditions, which could reduce patient volumes and increase bad debts. Inflation and rising interest rates directly impact the company due to its $1.08 billion in variable-rate debt, increasing interest expense. Labor costs are under pressure from minimum wage increases, especially in California (effective 2025), and a shortage of radiologists and technologists.
Government payors (Medicare 25%, Medicaid 3%) are critical. The 2026 Medicare Physician Fee Schedule final rule could reduce rates. Managed care contracting is competitive, with capitation arrangements (6% of revenue) passing financial risk to RadNet. Compliance with anti-kickback, Stark, and corporate practice of medicine laws is complex; violations could result in severe penalties. Regulatory changes under the new administration are uncertain.
Technological advances, including AI, could render equipment obsolete. RadNet's AI investments (DeepHealth, Aidence, etc.) carry execution risk; past impairment of $3.9 million shows potential for losses. Cybersecurity threats are elevated; a major breach could disrupt operations and expose sensitive data, as highlighted by the Change Healthcare incident.
Competition from hospitals and private equity-backed chains pressures pricing. The company depends on contracted radiology groups; their termination would materially harm revenue. Physicians referring patients have no contractual obligation, creating volume risk. Acquisitions (35 centers in 3 years) require successful integration.
High fixed costs mean small revenue changes disproportionately impact margins. Debt covenants restrict dividends and investments. Goodwill impairment is a risk if acquisitions underperform. Insurance costs may rise, and stock price volatility could attract securities litigation.
RadNet's operating cash flow (CFO) of $298.8M in FY2025 comfortably exceeded net income of $17.0M, driven by large non-cash items: depreciation & amortization ($152.1M), non-cash lease expense ($59.9M), and stock-based compensation ($54.6M). CFO improved 28% YoY, outpacing net income growth (net income was $38.8M in 2024). CapEx intensity (CapEx/CFO) was 71%, up from 81% in 2024, indicating higher reinvestment. Free cash flow (not explicitly stated) would be roughly $85.6M (CFO minus CapEx). The company did not pay dividends or repurchase shares; instead, it used cash for acquisitions ($133.4M) and debt repayments. Working capital changes consumed $47.8M, driven by accounts receivable and other assets. Overall, operating cash flow generation remains healthy, supporting growth investments and debt reduction.